Investor Newsletter

Issue 05 2021

MicroPort®

MicroPort® Firehawk Liberty™ Registration Approved in Belarus

The Firehawk Liberty™ Rapamycin Target Eluting Coronary Stent System ("Firehawk Liberty™"), developed by Shanghai MicroPort Medical Group Co., Ltd. (MicroPort®), has received registration approval from the Ministry of Health of Belarus.

Firehawk Liberty™ is a drug-eluding stent (DES) that features strut in-groove coating and precision target drug-releasing patent technology. It utilizes innovative stent balloon technology to optimize expansion performance, offering better crossability, traceability and pushability, and thus further optimizing the vessel wall apposition of the stent.

With nearly 600 grooves evenly cut in the hair-thin but extremely hard CoCr alloy, Firehawk Liberty™ combines the advantages of both the bare metal stent and drug-eluting stent. The stent allows for the precise injection of drugs into the micro-grooves by means of a fully automatic 3D-printed micro-groove filling, ensuring the effectiveness of the drug whilst significantly reducing the drug loading.

The approval of Firehawk Liberty™ has broadened the coronary intervention product line of MicroPort® in Belarus, further expanding the global footprint of MicroPort® medical products. In the future, MicroPort® aims to continue introducing more high quality and innovative medical devices to overseas markets, so as to offer a complete medical solution for patients around the world.

MicroPort

FUTURE-II Trial shows MicroPort®'s Firesorb® bioresorbable scaffold is comparable in angiographic and clinical efficacy to the world's leading coronary drug-eluting stents

On 19 May 2021, MicroPort® Scientific Corporation (MicroPort®) announced positive one-year imaging and clinical results of the FUTURE-II Trial, a pivotal study designed to produce the clinical data in support of the registration requirements for China's National Medical Products Administration (NMPA) approval. Prof. Bo Xu from Fu Wai Hospital, National Center for Cardiovascular Diseases in Beijing, China, presented the results alongside the co-principal investigator in a late-breaking trial session at the EuroPCR 2021 congress, held in Paris, France.

The FUTURE-II Trial compared the safety and efficacy of Firesorb® to a market-leading cobalt-chromium everolimus-eluting metallic stent (CoCr-EES) (XIENCE, Abbott). The primary endpoint of 1-year angiographic in-segment late loss (LL) was 0.17±0.27 mm in the Firesorb® BRS group and 0.19±0.37 mm in the XIENCE group. The Firesorb® RRS was non-inferior to XIENCE for the primary endpoint of one-year angiographic in-segment LL. The key secondary endpoint of one-year proportion of covered struts assessed by optical coherence tomography (OCT) was 99.3% in the Firesorb® BRS group and 98.8% in XIENCE group (Pnoninferiority<0.0001).

Principal investigator of the FUTURE-II Trial, Prof. Runlin Gao, from Fu Wai Hospital, National Center for Cardiovascular Diseases, said, "The results of FUTURE-II show that Firesorb® BRS provides comparable results at one-year to a best-in-class drug eluting stent in traditional endpoints, providing clinicians with additional confidence to use PLLA-based BRS to treat their patients."

EuroPCR 2021 announced the 4-year long term follow-up results of TARGET AC study with Firehawk® coronary rapamycin targeted eluting stent system

MicroPort Scientific Corporation (Microport®) released the 4 year long-term follow-up results of the clinical trial of Firehawk® coronary rapamycin targeted eluting stent system (Firehawk®) in a broad all-comers population, referred to as 'Target AC'. Professor Andreas Baumbach, Chair of Device Research and Director of Interventional Cardiology Research from the Heart Center of Queen Mary University of London, UK, revealed the results at 2021 EuroPCR.

In his presentation, Professor Baumbach stated that the 4 years target lesion failure occurred in compare groups of Firehawk® and Xience is 14.6% and 13.7% respectively, and no statistic difference(p-value=0.62). In addition, the results of the detail measurements fully agree with this composite end point. The cardiac death is 3.3% vs. 2.8% (P=0.54), the target vessel myocardial infarction is 9.2% vs. 9.3% (P=0.97), the ischemia-driven revascularization is 4.6% vs.5.7% (P=0.32) and the stent thrombosis rates is 2.3% vs. 2.9% (P=0.44). They are all no statistic difference.

These long-term follow up results strongly prove that Firehawk® and Xience are highly consistent in safety and effectiveness, allowing a step forward in international applications and providing a reliable choice for coronary heart disease patients and physicians worldwide.



A remarkable presence of MicroPort® CRM at the European EHRA congress

Microport® CRM recently participated in the annual congress of the European Heart Rhythm Association (EHRA) from April 23 - 25. This year, more than 3,300 delegates registered to attend the virtual congress, bringing together scientists, healthcare professionals and other players involved in cardiac arrhythmia management from across the globe.

Through a virtual booth, MicroPort® CRM used the congress as an opportunity to introduce their new line of pacemakers featuring Bluetooth® connectivity, AlizeaTM, associated with the SmartView ConnectTM home monitor.

A highlight of this digital event was the 30-minute symposium, sponsored by MicroPort® CRM, on 'Promising advances in heart failure patient management,' which featured the below line-up: Prof. Frédéric Anselme (University Hospital of Rouen, France) presented "A new route to left ventricular pacing leveraging the Axone lead project"; Prof. Martin Cowie (Imperial College London, United Kingdom) talked about "Emerging opportunities with digital health solutions to improve heart failure patient management"; A live Q&A moderated by Prof. Francisco Leyva (Queen Elizabeth Hospital, Birmingham, United Kingdom).

Francisco LEYVA
(Birmingham - GB)

Frederic ANSELME
(Rouen Cedex - FR)

Martin COWIE
(London - GB)

CardioFlow Medtech Announces Four-Year Follow-Up Results of VitaFlow® Clinical Trial during CIT 2021

MicroPort CardioFlow Medtech Corporation (CardioFlow) recently held a satellite session on 'Innovative Design and Four-year Clinical Results of VitaFlow® at The 19th China Interventional Therapeutics Congress (CIT 2021), announcing the four-year follow-up results of the clinical study of the VitaFlow® Transcatheter Aortic Valve and Delivery System (VitaFlow®).

During the sesssion, Prof. Daxin Zhou, from Zhongshan Hospital Affiliated to Fudan University, presented the innovative design of the VitaFlow® and the four-year follow-up results of the clinical study – a prospective, multi-centre, single-arm study, which enrolled 110 patients with severe aortic stenosis not suitable for open-heart intervention. Encouragingly, results of the four-year follow-up also demonstrate the high safety and efficacy of VitaFlow® in the treatment of elderly patients with severe aortic stenosis, proving the effectiveness of long-term use.

Academician Junbo Ge, from Zhongshan Hospital Affiliated to Fudan University, was invited to serve as the guest chairperson. During his address to the congress, Academician Ge said, "After more than a decade of efforts and many breakthroughs, signs of progress have been made in the field of interventional therapy of aortic valve disease in China. TAVR technology, which has been termed as the 'fourth revolution' in the cardiovascular field, is now being rapidly adopted in major hospitals across China. As population aging intensifies in China, the number of patients with heart valve disease will increase, which will further expand the clinical application of TAVR technology. Against this context, it is crucial to encourage our colleagues to exchange information, share knowledge and discuss the latest issues."



MicroPort® NeuroTech Numen® System and Controller Receive CE Mark

The Numen® Coil Embolization System (Numen®) and Numen FR® Coil Detachment System (Numen FR®), developed by Shanghai MicroPort NeuroTech Co., Ltd. (MicroPort® NeuroTech), recently received the CE Mark certification by the European Union. Previously, Numen® and Numen FR® were approved for marketing in China in 2020 and have been highly recognized by physicians and patients for their clinical performance.

The Numen® Coil Embolization System, with its stable baskets and dense packing, is primarily used in coil embolization procedures for the treatment of intracranial aneurysm. Numen® is available in different sizes, providing physicians a full range of embolization options for intracranial aneurysm and helping ensure the safety and efficacy of the procedures. The Numen FR® Coil Detachment System is for use in conjunction with the Numen® Coil Embolization system to assist in coil detachment.

"We always strive to provide a complete medical solution for patients with cerebral stroke", said Zhiyong Xie, President of MicroPort® NeuroTech, "Our success in obtaining CE Mark certification for the Numen® products is an important recognition and a new starting point for us. MicroPort® NeuroTech will invest more resources in research and development to provide more quality and innovative solutions on cerebrovascular and neuro interventions for physicians and patients, both at home and abroad."

MicroPort

MicroPort® EP Receives Registration Approval from Kazakhstan Ministry of Health for Multiple Products

Shanghai MicroPort EP MedTech Co., Ltd. ("MicroPort® EP") has recently obtained registration approval from the Ministry of Health of Kazakhstan ("MOH") for multiple independently-developed products, marking its first entry into the Kazakhstani market.

In total, 17 devices and catheters were approved for use, including the Columbus® 3D EP Navigation System, the OptimAblate® Cardiac RF Generator, the OptimAblate® Irrigation Pump, the FireMagic® Cardiac RF Ablation Catheter Series, the EasyFinder® Diagnostic Catheter Series, the EasyLoop® Circular Mapping Catheter Series, the PathBuilder® Introducer Sets and the FORLNK™ Cable Series, which are primarily used for the diagnosis and effective treatment of cardiac arrhythmias.

In recent years, MicroPort® has been actively contributing to the "Belt and Road" Initiative by providing total medical solutions for doctors and patients in countries along the route. Responding to the situation that some "Belt and Road" countries are poorly equipped with medical equipment and have a limited number of surgeons who have received systematic training on minimally invasive surgery, MicroPort® has launched a number of projects over the years to provide education and exchange opportunities for local doctors, disseminating the latest information and sharing clinical experiences.

In the future, MicroPort® will continue to provide products and develop an academic exchange platform for medical professionals from the "Belt and Road" countries to support their training of professional techniques for the benefit of patients worldwide.



Columbus™ 3D EP Navigation System

OptimAblate™ Cardiac RF Generator

OptimAblate™ Irrigation Pump

MicroPort® EP Columbus® 3D EP Navigation System Successfully Performs First Procedure in Brazil

The Columbus 3D EP Navigation System (Columbus®), developed by Shanghai MicroPort® EP MedTech Co., Ltd. ("MicroPort® EP"), has successfully performed its first procedure in Brazil. The successful procedure for atrial fibrillation, associated with atrial flutter, marked the first 3D procedure using MicroPort® products in Brazil since MicroPort® EP entered the Brazilian market. This makes it the fourth Latin American country to have successfully completed 3D procedures with Columbus®, following the Dominican Republic, Argentina and Ecuador.

The procedure, which also saw the use of MicroPort® EP's ancillary FireMagic® Cool 3D Irrigated Ablation Catheter and EasyLoop® Circular Mapping Catheter, was performed by a team led by Dr. Angêlo de Paola at Hospital São Paulo. MicroPort®'s Columbus® was highly regarded by the team for its robust performance and clear and stable EP recording system feature. After the procedure, the team expressed their hope to further explore arrhythmia treatment solutions together with MicroPort® EP in the future.

Dr. Yiyong Sun, President of MicroPort® EP, said, "To date, MicroPort® EP products and services have reached more than 20 countries and regions, including Asia, Europe, Africa, Latin America and Oceania, providing doctors and patients with cardiac arrhythmias with a comprehensive EP solution. In the future, MicroPort® EP will continue to focus on innovation and development, offering world-class comprehensive solutions for electrophysiological interventions, to benefit more doctors and patients around the world with quality products and services. "

MicroPort® RehabTech Group holds its Inauguration Ceremony in Shanghai

On 14 May 2021, RIC MedTech (Suzhou) Co., Ltd. ("MicroPort® RIC") has merged with Shanghai Shentai Medical Technology Co., Ltd. ("MicroPort® Shentai") to create MicroPort® RehabTech Group.

MicroPort® started to plan its rehabilitation business in 2017, with the aim of not only saving lives and curing diseases, but also helping patients to recover their body functions and return to normal life as soon as possible. MicroPort® established two subsidiaries for rehabilitation business, MicroPort® RIC and MicroPort® Shentai, in May 2018 and January 2019 respectively, which focus on muscle and bone rehabilitation, cardiopulmonary rehabilitation and neurological rehabilitation. Thanks to nearly three years of R&D investment, MicroPort® has obtained nearly 100 patents in rehabilitation medicine and has several products already available for use on the market; numerous other rehabilitation products have entered the registration stage, with the aim of launching in the next two years.

Mr. Yi LUO, General Manager of MicroPort RehabTech Group, commented, "clinical medicine plus rehabilitation medicine, the application of smart IoT technology in rehabilitation medicine, home- and community-based rehabilitation, and the flourishing private rehabilitation market will be the four major trends in the development of China's rehabilitation medicine. MicroPort® RehabTech Group will be service-oriented and fulfill the clinical needs and pain points. We will also take full advantage of our strengths in R&D, product quality, channels and brand, provide high-quality rehabilitation therapeutic solutions and services for the patients."

MicroPort® RIC MedTech Exhibits at CMEF 2021

MicroPort® RIC MedTech (Shanghai) Co., Ltd. (MicroPort® RIC) recently showcased a range of rehabilitation devices at the 84th China International Medical Equipment Fair (CMEF 2021). This year, the CMEF had the theme 'Innovative Technology for an Intelligent Future', and was held at the China National Convention and Exhibition Center in Shanghai.

At the fair, MicroPort® RIC highlighted its total medical solution for clinical therapy-based rehabilitation, which includes acute and sub-acute solutions for musculoskeletal rehabilitation, cardiopulmonary rehabilitation solutions, rehabilitation care solutions and home rehabilitation solutions.

Mr Yi Luo, General Manager of MicroPort® RehabTech Group, commenting on MicroPort® RehabTech Group's latest product developments, said, "MicroPort® RehabTech Group will adopt a locally rooted yet globally oriented mindset with a dedicated focus on the rehabilitation field, and develop a product strategy that covers the full rehabilitation cycle and is driven by continuous innovation"

As part of its musculoskeletal acute rehabilitation portfolio, MicroPort® RIC's new TherMotion™ Cryo-Thermo compression system drew wide attention by its semiconductor-based cooling and heating with intermittent compression, which is expected to enable rapid and precise acceleration or reduction of blood circulation, tissue metabolism and other responses. In addition, its independent chamber design allows for the application of alternating hot and cold treatment and intermittent compression, which is expected to address the pain points of slow cooling, susceptible to cold injury, and low patient compliance that may result from using ice and water mixture or single hot and cold patch for inflammatory responses in postoperative treatment or during the acute phase of injury.

MicroPort® Subsidiary EndoPhix® Performs World's First Permanently Implanted Balloon Rotator Cuff Functional Reconstruction Surgery

The first implantation of the Archimedes® Balloon Rotator Cuff Reconstruction System (the Archimedes® device), developed by Shanghai EndoPhix Medical Technology Company Limited (EndoPhix®), a subsidiary of MicroPort Scientific Corporation (MicroPort®, 00853.HK), was successfully performed at the Shanghai Sixth People's Hospital affiliated to Shanghai Jiaotong University on May 26 2021. As the first balloon implantation procedure for rotator cuff tears in China, it marks the first time that domestic patients have benefited from the world's most cutting-edge concept of balloon implantation related procedures and devices for rotator cuff repair.

Prof. Jinzhong Zhao, commented, "The Archimedes® device offers a new treatment option to patients with severe rotator cuff injuries. This treatment is minimally invasive with a short operating time and a simple learning curve, making it ideal for widespread adoption and implementation. Compared to traditional suture or anchor repair techniques, it provides immediate symptom relief as well as significant improvement in shoulder activity, greatly contributing to rapid postoperative pain-free rehabilitation and muscle strength recovery."

Gude Wang, Chief Operating Officer and Chairman of the Sports Medicine Operation of MicroPort®, said, "The Archimedes® device is not only China's first balloon treatment solution for rotator cuff injuries, but also the world's first rotator cuff balloon system developed for truly permanent implantation. When developing this new technology, MicroPort® Sports Medicine and surgical experts have worked innovatively together to fill gaps in relevant fields at native and abroad by securing sufficient international patents, and at the same time provide a new, economical and efficient treatment solution."

MicroPort

Investor Newsletter

Issue 05 2021

MicroPort®

For more information, please contact:

Martin Sun
Chief Financial Officer
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com

Leanne Li
Board Secretary & VP of Securities Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com